Mycenax and Spera forge alliance to streamline ADC drug substance

Mycenax Biotech, a leading biologics CDMO based in Taiwan, announced a strategic alliance with Spera Pharma, a Japan-based expert in pharmaceutical Chemistry, Manufacturing, and Controls (CMC).

The collaboration combines the complementary strengths of both organizations to provide a comprehensive solution for antibody-drug conjugates (ADCs) and bioconjugates, encompassing linker/payload synthesis, drug substance production, formulation, and aseptic fill-finish.

The alliance is designed to accelerate time-to-market for biopharmaceutical companies by offering an integrated, cost-effective ADC development and manufacturing platform. By leveraging Mycenax’s end-to-end biologics capabilities, enhanced through its partnership with KriSan Biotech, together with Spera Pharma’s expertise in CMC and high-potent fill-finish services for ADCs, the two companies are creating a one-stop solution tailored to the needs of global clients.

Founded in 2017 as a spin-off from Takeda Pharmaceutical Company’s CMC Research Division, Spera Pharma is recognized for its extensive experience in complex drug development, spanning process chemistry, formulation, analytical development, and GMP-compliant aseptic manufacturing. As one of Japan’s leading CDMOs, Spera Pharma has earned the trust of global partners for its technical excellence and integrated CMC services.